29 January 2021 - Managed entry agreements are increasingly used to address uncertainties arising in the health technology assessment process due to immature evidence of new, high cost medicines on their real world performance and cost effectiveness. 

The literature remains inconclusive on the health technology assessment decision-making factors that influence the utilisation of managed entry agreements.

The researchers aimed to assess if the uptake of managed entry agreements differs between countries and if so, to understand which health technology assessment decision-making criteria play a role in determining such differences.

Read International Journal of Technology Assessment in Health Care article